ASX Penny Stocks To Watch In January 2025

The Australian market has recently seen a downturn, with the ASX200 slipping 0.6% to 8,280 points amidst concerns over upcoming US jobs data and warnings from Goldman Sachs about potential corrections in US stocks. Despite this cautious climate, investors can find intriguing opportunities by exploring penny stocks—companies that are often smaller or newer but may offer surprising potential. While the term "penny stocks" might seem outdated, these investments can still provide value when backed by strong financials and growth prospects, making them worth considering for those looking beyond the usual market giants.

Top 10 Penny Stocks In Australia

Name	Share Price	Market Cap	Financial Health Rating
Embark Early Education (ASX:EVO)	A$0.77	A$141.28M	★★★★☆☆
LaserBond (ASX:LBL)	A$0.565	A$66.23M	★★★★★★
Austin Engineering (ASX:ANG)	A$0.52	A$322.48M	★★★★★☆
SHAPE Australia (ASX:SHA)	A$2.86	A$237.13M	★★★★★★
SKS Technologies Group (ASX:SKS)	A$1.59	A$249.92M	★★★★★★
Vita Life Sciences (ASX:VLS)	A$1.915	A$107.38M	★★★★★★
Helloworld Travel (ASX:HLO)	A$1.99	A$324.01M	★★★★★★
MaxiPARTS (ASX:MXI)	A$1.90	A$105.1M	★★★★★★
Navigator Global Investments (ASX:NGI)	A$1.615	A$791.48M	★★★★★☆
Servcorp (ASX:SRV)	A$4.95	A$488.39M	★★★★☆☆

Click here to see the full list of 1,051 stocks from our ASX Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

EVZ (ASX:EVZ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: EVZ Limited, with a market cap of A$21.24 million, operates in the engineering services sectors across Australia and Asia through its subsidiaries.

Operations: The company's revenue is derived from its Building Products segment, which generated A$38.96 million, and its Energy and Resources segment, contributing A$79.96 million.

Market Cap: A$21.24M

EVZ Limited, with a market cap of A$21.24 million, presents an intriguing option within the penny stock category due to its strong financial metrics and operational stability. The company has no debt and boasts high-quality earnings, with short-term assets significantly exceeding both short-term and long-term liabilities. Its price-to-earnings ratio of 9.9x is favorable compared to the broader Australian market average of 19.8x, suggesting potential undervaluation. Despite a low return on equity at 6.5%, EVZ has demonstrated robust earnings growth over the past year (47.9%), surpassing industry averages, while maintaining stable weekly volatility at 10%.

• Take a closer look at EVZ's potential here in our financial health report.
• Explore historical data to track EVZ's performance over time in our past results report.

Great Divide Mining (ASX:GDM)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Great Divide Mining Ltd focuses on the exploration and development of mineral resource properties in Australia, with a market cap of A$11.06 million.

Operations: The company's revenue segment is entirely derived from Mineral Exploration and Resource Development, amounting to A$0.13 million.

Market Cap: A$11.06M

Great Divide Mining Ltd, with a market cap of A$11.06 million, is pre-revenue, focusing on mineral exploration in Australia. Despite being debt-free and having short-term assets (A$1.6M) that cover both short and long-term liabilities, the company faces challenges with less than a year of cash runway and recent shareholder dilution of 2.2%. The board's inexperience is notable with an average tenure of 1.9 years. While revenue grew significantly over the past year by a large margin, volatility remains high compared to most Australian stocks, indicating potential risks for investors seeking stability in penny stocks.

• Get an in-depth perspective on Great Divide Mining's performance by reading our balance sheet health report here.
• Gain insights into Great Divide Mining's past trends and performance with our report on the company's historical track record.

SciDev (ASX:SDV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SciDev Limited offers environmental solutions for water-intensive industries across Australia, the United States, Asia, and other international markets, with a market cap of A$108.22 million.

Operations: The company's revenue is primarily driven by its Chemical Services segment, which generated A$86.64 million, followed by the Water Technology segment with A$22.54 million.

Market Cap: A$108.22M

SciDev Limited, with a market cap of A$108.22 million, has demonstrated robust financial health by maintaining a debt-free status and achieving profitability over the past year. The company's Chemical Services segment significantly contributes to its revenue, generating A$86.64 million. Despite trading at 53.8% below estimated fair value, SciDev's return on equity remains low at 4.3%. Its short-term assets comfortably cover both short-term (A$20.1M) and long-term liabilities (A$1.6M). Recent board changes include the resignation of Director Simone Watt, potentially impacting strategic direction given her valuable industry insights over six years.

• Jump into the full analysis health report here for a deeper understanding of SciDev.
• Learn about SciDev's future growth trajectory here.

Make It Happen

• Discover the full array of 1,051 ASX Penny Stocks right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com